How to Monitor Brexpiprazole Plus Sertraline Treatment in PTSD
How should clinicians follow response and adverse effects when using brexpiprazole plus sertraline for posttraumatic stress disorder based on this trial?
When clinicians use brexpiprazole with sertraline for posttraumatic stress disorder, the key practical issue is when to expect separation from comparator treatment and what adverse effects to watch for. This trial provides a time course of improvement, flexible dose ranges, and specific safety signals that can structure follow-up.
-
Start once-daily combination treatment within the studied dose ranges
In the trial, brexpiprazole and sertraline were taken orally together once daily at the same time each day, without regard to meals. Dosing was flexible at brexpiprazole 1 to 3 mg per day and sertraline 100 to 200 mg per day, with titration over 2 to 3 weeks.
-
Set expectations that improvement may not be immediate
Counsel patients that this regimen did not show an early immediate separation signal. Greater improvement for brexpiprazole plus sertraline versus brexpiprazole plus placebo and versus placebo plus placebo was observed from Week 6 onward, and the primary efficacy endpoint was assessed at Week 10.
-
Track overall PTSD severity with repeated symptom measurement
The main efficacy measure in the trial was change in CAPS-5 total score from randomization to Week 10, with assessments at baseline and Weeks 1, 3, 6, 10, and 12. If using this evidence in practice, structured repeated measurement of overall PTSD severity is the most direct way to judge whether the patient is following the treatment pattern seen in the study.
-
Look for changes across specific symptom domains
At Week 10, the combination showed greater improvement than sertraline plus placebo in CAPS-5 Intrusion, Avoidance, and Negative cognitions and mood cluster scores, as well as CGI-S, PCL-5, HADS Anxiety, and HADS Depression. Monitor not only total PTSD burden but also whether intrusive symptoms, avoidance, mood and cognition symptoms, anxiety, and depressive symptoms are improving.
-
Monitor weight and somnolence during treatment
Weight increase and somnolence were the treatment-emergent adverse events with incidence of at least 10% in the brexpiprazole plus sertraline group. Mean weight change from randomization to last visit was +1.4 kg, and 4 of 80 participants experienced weight gain of at least 7%.
-
Assess for akathisia and other extrapyramidal symptoms
Extrapyramidal symptom-related treatment-emergent adverse events occurred in 13 of 80 participants, or 16.3%, in the brexpiprazole plus sertraline group. Akathisia is worth specifically asking about, even though mean changes on SAS, AIMS, and BARS were minimal across treatment groups.
-
Continue suicidality surveillance throughout treatment
Suicidality events occurred across groups in the trial, including one suicide attempt in the brexpiprazole plus sertraline arm. On the C-SSRS, treatment-emergent suicidal ideation at any visit occurred in 4 of 80 participants, or 5.0%, in the combination group, so ongoing suicide risk assessment remains necessary during follow-up.
Clinical Considerations
- Both brexpiprazole and sertraline were flexibly dosed, which reflects practice but limits dose-specific conclusions.
- The primary efficacy signal was present at Week 10 but not versus sertraline plus placebo at Week 12, which the authors attributed to end-of-trial improvement in the sertraline group.
- Most treatment-emergent adverse events were mild or moderate, but this was a 12-week trial and does not define longer-term safety.
- An established CAPS-5 meaningful within-patient change threshold was not available, which limits interpretation of clinical relevance for an individual patient.
Bottom Line
When using brexpiprazole plus sertraline for PTSD, monitor structured symptom change through at least 6 to 10 weeks and pay particular attention to weight, somnolence, akathisia or other extrapyramidal symptoms, and suicidality.
